Effect of Smoking on Postprandial Gastric Emptying, Glucose Tolerance and Secretion of Gut and Pancreatic Hormones
SmokinGLP-1
1 other identifier
interventional
24
1 country
1
Brief Summary
The study aims to evaluate the effect of smoking on postprandial responses such as plasma glucose, secretion of gut - and pancreatic hormones and gastric emptying in healthy, heavy smoking men.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable diabetes-mellitus
Started May 2015
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2015
CompletedFirst Submitted
Initial submission to the registry
June 25, 2015
CompletedFirst Posted
Study publicly available on registry
July 14, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2016
CompletedAugust 7, 2017
August 1, 2017
5 months
June 25, 2015
August 4, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Postprandial response of glucagon-like peptide-1 (GLP-1)
Incremental and total area under the Concentration-Time Curve (AUC 0-240 min)
-30, -20, -10, 0, 10, 20, 30, 50, 70, 90, 120, 150, 180, 240 minutes (meal tests start at 0 min)
Secondary Outcomes (10)
Postprandial response of insulin
-30, -20, -10, 0, 10, 20, 30, 50, 70, 90, 120, 150, 180, 240 minutes (meal tests start at 0 min)
Postprandial response of Glukagon
-30, -20, -10, 0, 10, 20, 30, 50, 70, 90, 120, 150, 180, 240 minutes (meal tests start at 0 min)
Postprandial response of CCK
-30, -20, -10, 0, 10, 20, 30, 50, 70, 90, 120, 150, 180, 240 minutes (meal tests start at 0 min)
Postprandial response of Gastrin
-30, -20, -10, 0, 10, 20, 30, 50, 70, 90, 120, 150, 180, 240 minutes (meal tests start at 0 min)
Postprandial response of GIP
-30, -20, -10, 0, 10, 20, 30, 50, 70, 90, 120, 150, 180, 240 minutes (meal tests start at 0 min)
- +5 more secondary outcomes
Study Arms (2)
Healthy, heavy smoking men
EXPERIMENTALTwelve healthy, male subjects. Intervention: Will undergo two separate, identical test days. One absent smoking, and one with concomitant smoking.
Healthy, non-smoking men
EXPERIMENTALTwelve healthy, male subjects. Intervention: Will undergo a liquid mixed meal test and a skin biopsy.
Interventions
The subjects will ingest a 400 ml chocolate drink, rich on carbohydrates, fat and lipids. In the following 4 hours, blood samples will be drawn from a PVC for the measurement of plasma glucose, gut- and pancreatic hormones, acetaminophen etc. After the 4 hours, the subjects will be offered an ad libitum meal.
All subjects will undergo a skin biopsy procedure. Two small (3 mm) biopsies will be taken from the hip area under local anaesthesia. Standard wound treatment will follow.
Eligibility Criteria
You may qualify if:
- Both groups
- Caucasian ethnicity
- Healthy males
- Normal haemoglobin
- Age above 18 years
- Informed and written consent
- BMI \>20 kg/m2
- Smokers • Minimum 20 cigarettes pr. day for at least 1 year
- Non-smokers
- No smoking on a regular basis
You may not qualify if:
- Both groups
- Diabetes or prediabetes (fasting plasma glucose levels \>6.5 mM or HbA1c \>6.0%)
- First- or second-degree relatives with diabetes
- Liver disease (alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) \>2 times normal values) or history of hepatobiliary disorder
- Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major intra-abdominal surgery
- Hypo- or hyperphosphataemia
- Nephropathy (serum creatinine \>150 µM and/or albuminuria
- Treatment with medicine that cannot be paused for 12 hours
- Hypo- or hypercalcaemia
- Hypo- and hyperthyroidism
- Treatment with oral anticoagulants
- Active or recent malignant disease
- Any treatment or condition requiring acute or sub-acute medical or surgical intervention
- Any condition considered incompatible with participation by the investigators
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital, Gentofte, Copenhagenlead
- University of Copenhagencollaborator
- European Foundation for the Study of Diabetescollaborator
Study Sites (1)
Center for Diabetes Research, Department of Medicine, Gentofte Hospital
Hellerup, Copenhagen, 2900, Denmark
Related Publications (1)
Grondahl MF, Bagger JI, Lund A, Faurschou A, Rehfeld JF, Holst JJ, Vilsboll T, Knop FK. Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers. Diabetes Care. 2018 Jun;41(6):1260-1267. doi: 10.2337/dc17-1818. Epub 2018 Mar 30.
PMID: 29602793DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
June 25, 2015
First Posted
July 14, 2015
Study Start
May 1, 2015
Primary Completion
October 1, 2015
Study Completion
June 1, 2016
Last Updated
August 7, 2017
Record last verified: 2017-08